Biofusion Share Discussion Threads

[thinkbig?] 29/6/2005 09:13

Nice move up first thing this morning means buyers in the back ground?

[thinkbig?] 28/6/2005 12:08

Found this on one of there RNS very interesting

Molecular Skincare* Topical treatment for skin diseases. In February
2005 Molecular Skincare was acquired by York
Pharma Plc and in March Biofusion took up its
option to acquire shares in York Pharma plc from
the University.

Spoken to the company and asked hows things! will there be any new developments did mention a bit about york pharma and molecular skincare going very well and a lot of interest in the product. The big thing is STEM CELL asked did you read the write up in the FT he said yes pity we did not get a mention? There could be a company spin off over the coming months if things go to plan.

[thinkbig?] 27/6/2005 10:20

Well did any body read the artical in the FT about Stem Cell very very good write up. Good to see the FT following the subject pity they did not name BFN as if they did more people will realies this company is going places. Did say it would be in the press. Looking for move up near end of day again and that would be the fourth move up in less than a week.

[thinkbig?] 24/6/2005 14:29

Well same as yesterday moving up in the afternoon expecting press coverage on this one over the weekend as stem cell is going to be very big in years to come and this company has got its feet in the door first. Price target still £1.50p

[thinkbig?] 23/6/2005 16:16

Moving up again near end of trading day looks like there is a buer in the back ground now? this share is going to move back to its IPO price looking for some press comment over the weekend

[shirishg] 23/6/2005 13:31

Post removed by ADVFN

[thinkbig?] 23/6/2005 13:30

Company coming to AIM with same plan and capped a lot higher than BFN hence the buying and mark up. This is just getting a re-rating

[thinkbig?] 23/6/2005 13:08

Did say this would move up news was just to good,for this not to move up. Still not to late 150p is still my target

[shirishg] 22/6/2005 14:13

Post removed by ADVFN

[thinkbig?] 22/6/2005 14:13

were is every one! not a post on this company

[thinkbig?] 21/6/2005 23:54

This company has great prospects over the coming months would expect more news as well soon,this should be in the papers tomorrow or could even get tipped over the weekend dont think many traders now about this gem but they soon will has a big porfoilio as well this is a none brainer look at mmg and what price they went to not saying this will go to £3 but it should get back to its float price now this news is out they hold a big stake in the company that has made the breakthrough.IMHO

[wh4tever8] 21/6/2005 23:47

Hi thinkBig,
Big news indeed and with undoubtedly very real applications in the fertility area, which is itself growing I believe. Regrettably I sold last month only through impatience. So is it time to buy back in?
Of course it would seem tricky to accurately research the current position of IP likely to be generated of commercial interest! However stem cells are a hot topic in the press at the moment, in this case commercial viability is presumably not so concerned with ethical issues and everything will already be specifically positioned for this kind of event.
Will watch with interest....8)

[thinkbig?] 21/6/2005 14:42

Just realeased

LONDON (AFX) - Biofusion PLC, which has a 10-year exclusive arrangement with
Sheffield University for the commercialisation of intellectual property in the
medical life sciences field, said it is positioned to exploit the university's
stem cell breakthrough.
The university's scientists, led by Professor Harry Moore, showed that human
embryonic stem cells can form the precursors of sperm and eggs in the
laboratory. The work opens up the possibility that stem cells could be used to
"rescue" testes and ovaries damaged by cancer treatment, or even to grow fully
fledged reproductive cells for use in fertility treatment.
"We look forward to developing any University of Sheffield IP derived in the
future from these observations," said chief executive David Baynes.
Moore is a founding director of Axordia Ltd, a company in which Biofusion
has a major shareholding.

[thinkbig?] 21/6/2005 14:32

Read this very interesting

Biofusion plc

Interim Results for the six months ended 31 January 2005

Biofusion plc "Biofusion or the Company", (AIM:BFN), the university IP
commercialisation company, announces its interim results for the six months
ending 31 January 2005.


Chairman, Doug Liversidge CBE, said

"I am delighted to present our interim results for the six months ending 31
January 2005. These are the first results we have issued since becoming a public
company on 2 February 2005. As a result of this timing we are in the unusual
position of presenting our results for the period that ended before the listing
was completed. Subsequent to the period end our business has been transformed by
the signing of an exclusive agreement with the University of Sheffield, by our
listing on AIM and the concurrent fund raising of #8.2m.

During the period, which preceded our recent IPO, the Company made a loss before
tax of #253,536 (2004: #83,454). In the main these costs related to our on-going
review of medical life science intellectual property (IP) produced at the
University and our evaluation of suitable opportunities for commercialisation.
In addition much effort was invested over the period in finalising the terms on
which the Company now owns IP exploitation rights emanating from the University
of Sheffield."

First agreement with University of Sheffield

During 2004, Biofusion finalised the details of its exclusive 10 year medical
life science agreement with the University of Sheffield (the "University"). By
taking a significant shareholding in Biofusion the University is the first
university in the UK to commercialise its IP in this way.

Biofusion's aim is to provide vital funding and start-up management skills to
turn academic research in the medical life sciences field into profitable
businesses. This approach enables the University and its world class academics
to focus on the creation of knowledge, knowing that they will have the potential
to be supported by the funds and development skills of the Biofusion management
team, significantly increasing the chances of successfully commercialising the
IP.

The University is ranked in the top 5 in the UK for research in medical life
sciences and is expected to spend a further #500 million over the next ten
years. The Directors believe that Biofusion is ideally placed to take commercial
advantage of the University's leading position in this area.

Company portfolio

As part of the agreement with the University, the University's shareholding in
eight companies and an economic interest in a ninth were transferred to
Biofusion at the time of the AIM listing. The Biofusion portfolio now includes
the following companies:

Company Sector/Business Description

Axordia Stem cell research and regenerative medicine

Asterion Cytokine agonists and antagonists

BioActa Anti-Angiogenesis factors

Diurnal Hormone replacement therapy that mimics the
circadian rhythm

Simcyp Simulation of virtual patient populations for use
in drug discovery and development

Plasso Surface engineering technology for life science
research

Adjuvantix Novel adjuvants for therapeutic and prophylactic
vaccines

Celltran Bioengineering technology for the treatment of
chronic wounds and burns

Molecular Skincare* Topical treatment for skin diseases. In February
2005 Molecular Skincare was acquired by York
Pharma Plc and in March Biofusion took up its
option to acquire shares in York Pharma plc from
the University.

*by way of an option to acquire Molecular Skincare shares from the University

Model Expansion

Since signing the agreement with the University of Sheffield and listing on AIM
we have had a number of discussions regarding the possibility of expanding our
model to include other leading British universities and we will continue to
pursue opportunities to expand our business model in this way.

New Board

We are delighted that during the period we were able to appoint Dr Edwin Moses
and Professor Tony Atkinson as non-executive directors to the board. Dr Moses is
a Sheffield alumnus and both are well respected within the academic and
investment community. Stuart Gall, one of the founding shareholders and members
of the management team, also joined the board and became a full-time employee in
April 2005.

Current Trading

It has clearly been an exciting period for the Company and the directors are
confident that we will achieve our target of creating a number of spin-out
companies in 2005 and exiting at least one of the existing companies within the
next 12 to18 months, if market conditions are suitable.

We look forward to the next financial year with considerable optimism.

[thinkbig?] 21/6/2005 14:23

Nobody follow this company,with news just announced thought people would be buying in this could easly go back to 150p with this breakthrough news out

[thinkbig?] 21/6/2005 14:15

This has come back from 150p a share this can only go one way now and that is up looks like mms have no stock as well and been caught with there pants down

[thinkbig?] 21/6/2005 14:09

Up 13 already looking for at least 20p by close very big news

[thinkbig?] 21/6/2005 14:07

21st June 2005

Biofusion plc

University of Sheffield Announcement of Stem Cell Breakthrough


As widely reported in the press the Board of Biofusion plc ("Biofusion")
acknowledges that scientists, led by Professor Harry Moore, at the University of
Sheffield have shown that human embryonic stem cells can form the precursors of
sperm and eggs in the laboratory. The work opens up the possibility that stem
cells could be used to "rescue" testes and ovaries damaged by cancer treatment,
or even to grow fully fledged reproductive cells for use in fertility treatment.
The results were announced yesterday at the European Society of Human
Reproduction and Embryology conference in Copenhagen.


David Baynes, CEO of Biofusion, said: "The University of Sheffield is at the
forefront of stem cell research and this announcement highlights the quality of
the medical and life science research conducted at the University. We look
forward to developing any University of Sheffield IP derived in the future from
these observations with Professor Moore and his team"


Professor Harry Moore is a founding director of Axordia Limited ("Axordia"), a
company in which Biofusion has a major shareholding. Axordia was founded in 2001
to design novel products using the properties of stem cells and their
derivatives. Axordia is developing products for drug discovery and products to
support and shorten the timeframe for the development of therapeutic treatments
for illnesses such as Parkinson's disease and diabetes.



Contacts


Biofusion
David Baynes/Stuart Gall [phone]


Citigate Dewe Rogerson
Chris Gardner/David Dible [phone]


About Biofusion

Biofusion was established in 2002 to commercialise university-generated IP. The
Company has agreed a ten-year exclusive arrangement with the University of
Sheffield for the commercialisation of IP owned by the University in the area of
medical life sciences. The agreement also gives Biofusion shareholdings in an
existing portfolio of eight spin out companies and an economic interest in a
ninth. A number of these companies, which are developing new medical solutions
in a number of exciting areas, have recently raised or are in the process of
raising funds and at least one is expected to be ready for exit within the next
12 to 24 months.



The University of Sheffield is a world class life sciences research centre,
spending #30m in 2002/3 on research in medical life sciences. This spending
level is expected to grow year on year giving an estimated #0.5bn of research
funding over the next ten years. The University, which celebrates its centenary
this year, can count five Nobel Prize winners among its alumni and researchers,
and data from the latest UK Government's Research Assessment Exercise 2001 ("RAE
2001") showed it ranked fifth in the UK for the quality of its life sciences
research.

[learntlesson] 17/6/2005 17:08

Please have a look and give your input here if your interested in identifying tech/engineering winners:



rgds,
LL

[shirishg] 09/3/2005 20:30

Post removed by ADVFN

[siri_edit] 09/3/2005 17:56

post removed by ADVFN

[shirishg] 09/3/2005 17:16

Post removed by ADVFN

[siri_edit] 09/3/2005 16:48

post removed by ADVFN